Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 7 8 2018
medline: 18 10 2019
entrez: 7 8 2018
Statut: ppublish

Résumé

This trial followed a structured nationwide training program in minimally invasive distal pancreatectomy (MIDP), according to the IDEAL framework for surgical innovation, and aimed to compare time to functional recovery after minimally invasive and open distal pancreatectomy (ODP). MIDP is increasingly used and may enhance postoperative recovery as compared with ODP, but randomized studies are lacking. A multicenter patient-blinded randomized controlled superiority trial was performed in 14 centers between April 2015 and March 2017. Adult patients with left-sided pancreatic tumors confined to the pancreas without vascular involvement were randomly assigned (1:1) to undergo MIDP or ODP. Patients were blinded for type of surgery using a large abdominal dressing. The primary endpoint was time to functional recovery. Analysis was by intention to treat. This trial was registered with the Netherlands Trial Register (NTR5689). Time to functional recovery was 4 days [interquartile range (IQR) 3-6) in 51 patients after MIDP versus 6 days (IQR 5-8) in 57 patients after ODP (P < 0.001). The conversion rate of MIDP was 8%. Operative blood loss was less after MIDP (150 vs 400 mL; P < 0.001), whereas operative time was longer (217 vs 179 minutes; P = 0.005). The Clavien-Dindo grade ≥III complication rate was 25% versus 38% (P = 0.21). Delayed gastric emptying grade B/C was seen less often after MIDP (6% vs 20%; P = 0.04). Postoperative pancreatic fistulas grade B/C were seen in 39% after MIDP versus 23% after ODP (P = 0.07), without difference in percutaneous catheter drainage (22% vs 20%; P = 0.77). Quality of life (day 3-30) was better after MIDP as compared with ODP, and overall costs were non-significantly less after MIDP. No 90-day mortality was seen after MIDP versus 2% (n = 1) after ODP. In patients with left-sided pancreatic tumors confined to the pancreas, MIDP reduces time to functional recovery compared with ODP. Although the overall rate of complications was not reduced, MIDP was associated with less delayed gastric emptying and better quality of life without increasing costs.

Sections du résumé

OBJECTIVE
This trial followed a structured nationwide training program in minimally invasive distal pancreatectomy (MIDP), according to the IDEAL framework for surgical innovation, and aimed to compare time to functional recovery after minimally invasive and open distal pancreatectomy (ODP).
BACKGROUND
MIDP is increasingly used and may enhance postoperative recovery as compared with ODP, but randomized studies are lacking.
METHODS
A multicenter patient-blinded randomized controlled superiority trial was performed in 14 centers between April 2015 and March 2017. Adult patients with left-sided pancreatic tumors confined to the pancreas without vascular involvement were randomly assigned (1:1) to undergo MIDP or ODP. Patients were blinded for type of surgery using a large abdominal dressing. The primary endpoint was time to functional recovery. Analysis was by intention to treat. This trial was registered with the Netherlands Trial Register (NTR5689).
RESULTS
Time to functional recovery was 4 days [interquartile range (IQR) 3-6) in 51 patients after MIDP versus 6 days (IQR 5-8) in 57 patients after ODP (P < 0.001). The conversion rate of MIDP was 8%. Operative blood loss was less after MIDP (150 vs 400 mL; P < 0.001), whereas operative time was longer (217 vs 179 minutes; P = 0.005). The Clavien-Dindo grade ≥III complication rate was 25% versus 38% (P = 0.21). Delayed gastric emptying grade B/C was seen less often after MIDP (6% vs 20%; P = 0.04). Postoperative pancreatic fistulas grade B/C were seen in 39% after MIDP versus 23% after ODP (P = 0.07), without difference in percutaneous catheter drainage (22% vs 20%; P = 0.77). Quality of life (day 3-30) was better after MIDP as compared with ODP, and overall costs were non-significantly less after MIDP. No 90-day mortality was seen after MIDP versus 2% (n = 1) after ODP.
CONCLUSIONS
In patients with left-sided pancreatic tumors confined to the pancreas, MIDP reduces time to functional recovery compared with ODP. Although the overall rate of complications was not reduced, MIDP was associated with less delayed gastric emptying and better quality of life without increasing costs.

Identifiants

pubmed: 30080726
doi: 10.1097/SLA.0000000000002979
doi:

Banques de données

NTR
['NTR5689']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2-9

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Auteurs

Thijs de Rooij (T)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

Jony van Hilst (J)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

Hjalmar van Santvoort (H)

Department of Surgery, St Antonius Hospital, Nieuwegein, and University Medical Center Utrecht, Utrecht, the Netherlands.

Djamila Boerma (D)

Department of Surgery, St Antonius Hospital, Nieuwegein, and University Medical Center Utrecht, Utrecht, the Netherlands.

Peter van den Boezem (P)

Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Freek Daams (F)

Department of Surgery, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.

Ronald van Dam (R)

Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands, and Universitätsklinikum Aachen, Aachen, Germany.

Cees Dejong (C)

Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands, and Universitätsklinikum Aachen, Aachen, Germany.

Eino van Duyn (E)

Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.

Marcel Dijkgraaf (M)

Clinical Research Unit, Amsterdam UMC, University of Amsterdam, the Netherlands.

Casper van Eijck (C)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

Sebastiaan Festen (S)

Department of Surgery, OLVG, Amsterdam, the Netherlands.

Michael Gerhards (M)

Department of Surgery, OLVG, Amsterdam, the Netherlands.

Bas Groot Koerkamp (B)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

Ignace de Hingh (I)

Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Department of Surgery, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.

Geert Kazemier (G)

Department of Surgery, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.

Joost Klaase (J)

Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.

Ruben de Kleine (R)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Cornelis van Laarhoven (C)

Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Misha Luyer (M)

Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.

Gijs Patijn (G)

Department of Surgery, Isala Clinics, Zwolle, the Netherlands.

Pascal Steenvoorde (P)

Department of Surgery, Isala Clinics, Zwolle, the Netherlands.

Mustafa Suker (M)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

Moh'd Abu Hilal (M)

Department of Surgery, Southampton University Hospital NHS Foundation Trust, Southampton, UK.

Olivier Busch (O)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

Marc Besselink (M)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH